Abpro Holdings, Inc. (ABPO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 0 | 2 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -8 | -5 | ||||||
| Net profit | $m | - | -15 | -17 | -12 | -7 | -3 | 2 | - |
| EPS reported | $ | -0.00 | 2.27 | ||||||
| Operating cashflow per share | $ | -0.00 | -1.02 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.00 | -1.02 | ||||||
| Free cash flow | $m | -6 | -6 | ||||||
| Net debt | $m | 0 | -4 | ||||||
| Book value equity | $m | 0 | -4 | ||||||
| Book value per share | $ | 0.00 | -0.60 | ||||||
| Number of shares | m | 2,232.61 | 5.9 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.00 | -2,673.07 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -1,572.42 | -1,564.86 | ||||||
| EV/EBITDA LTM | x | -41,973.42 | 2,360.41 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -0.03% | +1.49% | ||||||
| FCF Yield | % | -0.06% | -0.06% | ||||||
| Quality | |||||||||
| ROE | % | 0.00% | -35.79% | ||||||
| ROIC | % | +1.04% | +1.90% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -100.00% | -100.00% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -40.86 | -35.29 | ||||||
| Net Debt/EBITDA | x | -0.36 | -1.02 | ||||||
| EBIT/Net interest | x | -3.79 | 2.62 | ||||||
| Net debt/market cap | % | +0.00% | +27.86% | ||||||
| Net debt/Equity | x | - | 1.15 | ||||||
| Gross debt/equity | x | - | -0.05 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Abpro Holdings, Inc. is a biotechnology firm specializing in the creation of innovative antibody treatments, primarily targeting immuno-oncology and ophthalmology. The company leverages two proprietary technological platforms: DiversImmune, a discovery platform that identifies a broad spectrum of unique antibodies against both established and emerging therapeutic targets, and MultiMab, an engineering platform offering the versatility to assemble antibody components into customized, multi-specific constructs tailored for specific therapeutic needs. Abpro's flagship therapeutic pipeline includes ABP-102, a next-generation immuno-oncology TetraBi antibody engineered to dually target HER2 and CD3, offering a potential treatment for HER2-positive solid tumors like breast and gastric cancers. Another key candidate, ABP-201, is a TetraBi antibody designed to simultaneously inhibit both VEGF and ANG-2 pathways for the management of vascular eye diseases, such as diabetic macular edema and wet age-related macular degeneration. The company's pipeline also features ABP-110, a TetraBi antibody targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, another TetraBi antibody focused on claudin 18.2 and CD3 for gastric cancers. Abpro maintains strategic alliances with Celltrion Inc. and Abpro Bio International, Inc. Established in 2004, Abpro Holdings, Inc. is headquartered in Woburn, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Abpro Holdings, Inc. is a biotechnology firm specializing in the creation of innovative antibody treatments, primarily targeting immuno-oncology and ophthalmology. The company leverages two proprietary technological platforms: DiversImmune, a discovery platform that identifies a broad spectrum of unique antibodies against both established and emerging therapeutic targets, and MultiMab, an engineering platform offering the versatility to assemble antibody components into customized, multi-specific constructs tailored for specific therapeutic needs. Abpro's flagship therapeutic pipeline includes ABP-102, a next-generation immuno-oncology TetraBi antibody engineered to dually target HER2 and CD3, offering a potential treatment for HER2-positive solid tumors like breast and gastric cancers. Another key candidate, ABP-201, is a TetraBi antibody designed to simultaneously inhibit both VEGF and ANG-2 pathways for the management of vascular eye diseases, such as diabetic macular edema and wet age-related macular degeneration. The company's pipeline also features ABP-110, a TetraBi antibody targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, another TetraBi antibody focused on claudin 18.2 and CD3 for gastric cancers. Abpro maintains strategic alliances with Celltrion Inc. and Abpro Bio International, Inc. Established in 2004, Abpro Holdings, Inc. is headquartered in Woburn, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free